Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 94Prostatic Neoplasms, Castration-Resistant 10Neoplasm Metastasis 8Breast Neoplasms 8Neoplasms 7Triple Negative Breast Neoplasms 4Metastatic Castration-Resistant Prostate Cancer 4Carcinoma, Non-Small-Cell Lung 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Bulbo-Spinal Atrophy, X-Linked 3Adenocarcinoma 3mCRPC 2Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Prostate Adenocarcinoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Bites and Stings 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor 1

Interventions

Radiotherapy 3Radiation 3Magnetic Resonance Spectroscopy 3relugolix 2luprolide acetate gel depot 2enzalutamide 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Specimen Handling 2Radiosurgery 2Leuprolide 2Goserelin 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1gallium 68 PSMA-11 1darolutamide 1abiraterone 1X-Rays 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Salicylic Acid 1Radium-223 1Radiotherapy, Image-Guided 1Radiation Dose Hypofractionation 1Proton Therapy 1Prednisone 1Lymph Node Excision 1Glutamate Carboxypeptidase II 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × enzalutamide × 1 year × Clear all
NCT06499870 2026-06-05

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT06257693 2026-02-27

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Alessa Therapeutics Inc.

Phase 1 Recruiting
56 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡